Engler M, Albers D, von Maltitz P, Gro xdf R, M xfc nch J, Cirstea I. ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection. Life Sci Alliance. 2023;6: pubmed publisher

Mart xed nez M xe1 rmol R, Giordano Santini R, Kaulich E, Cho A, Przybyla M, Riyadh M, et al. SARS-CoV-2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity. Sci Adv. 2023;9:eadg2248 pubmed publisher

Baciu D, Dinu S, Palade B, Onu A, Costache A. Comparison of truncated human angiotensin-converting enzyme 2 (hACE2) expression in pET28a(+) versus pET-SUMO vector and two Escherichia coli strains. Adv Med Sci. 2023;68:61-70 pubmed publisher

Andreano E, Paciello I, Pierleoni G, Piccini G, Abbiento V, Antonelli G, et al. B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response. Nat Commun. 2023;14:53 pubmed publisher

Charles J, McCann N, Ploplis V, Castellino F. Spike protein receptor-binding domains from SARS-CoV-2 variants of interest bind human ACE2 more tightly than the prototype spike protein. Biochem Biophys Res Commun. 2023;641:61-66 pubmed publisher

Brasu N, Elia I, Russo V, Montacchiesi G, Stabile S, De Intinis C, et al. Memory CD8+ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination. Nat Immunol. 2022;23:1445-1456 pubmed publisher

Compagnone M, Pinto E, Salvatori E, Lione L, Conforti A, Marchese S, et al. DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model. Vaccines (Basel). 2022;10: pubmed publisher

Aicher S, Streicher F, Chazal M, Planas D, Luo D, Buchrieser J, et al. Species-Specific Molecular Barriers to SARS-CoV-2 Replication in Bat Cells. J Virol. 2022;96:e0060822 pubmed publisher

Andreano E, Paciello I, Marchese S, Donnici L, Pierleoni G, Piccini G, et al. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees. Nat Commun. 2022;13:3375 pubmed publisher

Vanhulle E, Stroobants J, Provinciael B, Camps A, Noppen S, Maes P, et al. SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening. Antiviral Res. 2022;203:105342 pubmed publisher

Torres J, Ozorowski G, Andreano E, Liu H, Copps J, Piccini G, et al. Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Proc Natl Acad Sci U S A. 2022;119:e2120976119 pubmed publisher

Shah M, Ung Moon S, Hyun Kim J, Thanh Thao T, Goo Woo H. SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. Comput Struct Biotechnol J. 2022;20:2042-2056 pubmed publisher

Francesconi O, Donnici L, Fragai M, Pesce E, Bombaci M, Fasciani A, et al. Synthetic carbohydrate-binding agents neutralize SARS-CoV-2 by inhibiting binding of the spike protein to ACE2. iScience. 2022;25:104239 pubmed publisher

Barrow K, Wang Y, Yu R, Zhu J, Yang G. H2S protects from oxidative stress-driven ACE2 expression and cardiac aging. Mol Cell Biochem. 2022;477:1393-1403 pubmed publisher

Villa A, Brunialti E, Dellavedova J, Meda C, Rebecchi M, Conti M, et al. DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic. Pharmacol Res. 2022;175:105982 pubmed publisher

Shin J, Toyoda S, Nishitani S, Fukuhara A, Kita S, Otsuki M, et al. Possible Involvement of Adipose Tissue in Patients With Older Age, Obesity, and Diabetes With SARS-CoV-2 Infection (COVID-19) via GRP78 (BIP/HSPA5): Significance of Hyperinsulinemia Management in COVID-19. Diabetes. 2021;70:2745-2755 pubmed publisher

Brune K, Lieknina I, Sutov G, Morris A, Jovicevic D, Kalnins G, et al. N-Terminal Modification of Gly-His-Tagged Proteins with Azidogluconolactone. Chembiochem. 2021;22:3199-3207 pubmed publisher

Youn J, Zhang Y, Wu Y, Cannesson M, Cai H. Therapeutic application of estrogen for COVID-19: Attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells. Redox Biol. 2021;46:102099 pubmed publisher

Li X, Lidsky P, Xiao Y, Wu C, Garcia Knight M, Yang J, et al. Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. PLoS Pathog. 2021;17:e1009898 pubmed publisher

García Ayllón M, Moreno Pérez Ó, García Arriaza J, Ramos Rincón J, Cortés Gómez M, Brinkmalm G, et al. Plasma ACE2 species are differentially altered in COVID-19 patients. FASEB J. 2021;35:e21745 pubmed publisher

Li X, Lidsky P, Xiao Y, Wu C, Garcia Knight M, Yang J, et al. Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models. bioRxiv. 2020;: pubmed publisher

Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221-224 pubmed publisher